Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha ...

Amgen’s Repatha and Sanofi/Regeneron’s Praluent are competing for market share in the new class of PCSK9 inhibitors for high-risk cholesterol patients after both were approved by FDA this summer.

A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for ...

Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.

Amgen had earlier begun individual negotiations with insurers, reducing the price of Repatha to the Harvard Pilgrim health plan, for example, and agreeing to refund the cost of the drug to any ...

The launch of Amgen's new cholesterol-lowering drug Repatha is renewing the debate over the cost of drugs and the reasons why prices are so much higher in the U.S. than in other advanced countries.

THOUSAND OAKS, Calif., Nov. 16, 2019 /PRNewswire/ -- Amgen today announced a new analysis from the Repatha® (evolocumab) cardiovascular outcomes ( ...

Repatha costs more than $14,000 a year; many of its users are likely to need it all their lives. But when it introduced its RepathaReady financial assistance program, Amgen required enrollees to ...

Commercializing Amgen's recently approved cholestserol fighter Repatha across the EU hit a road block this week when cost crunchers in the U.K. determined that the drug didn't deliver the right ...

The drugmaker said Repatha would start with a list price of $14,100 for a year’s worth of treatment. Developed by Amgen’s scientists, it is the second in a new class of drugs that lower ...

THOUSAND OAKS, Calif., Oct. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that effective Dec. 31, 2019, Repatha® (evolocumab), an innovative treatment for patients with high ...